LPL and Other metabolic disease: Recently, Sparcl1 was reported to have a negative effect during preadipocyte differentiation and inhibits lipid droplet accumulation through regulating peroxisome proliferator-activated receptor-gamma (PPARγ), lipoprotein lipase (LPL) and insulin-like growth factor 1 (7), suggesting that Sparcl1 might play an important role in the development of metabolic disease.